Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Solomon Epstein

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Current Osteoporosis Reports|March 11, 2006
Ibandronate treatment for osteoporosis: rationale, preclinical, and clinical development of extended dosing regimensSolomon Epstein
Clinical Therapeutics|May 9, 2006
Update of current therapeutic options for the treatment of postmenopausal osteoporosisSolomon Epstein
Mayo Clinic Proceedings|March 11, 2005
The roles of bone mineral density, bone turnover, and other properties in reducing fracture risk during antiresorptive therapySolomon Epstein
Annals of the New York Academy of Sciences|July 13, 2006
Nonsteroid immune modulators and bone diseaseRonald Tamler, Solomon Epstein
Reviews on Recent Clinical Trials|May 26, 2009
Evaluating the antifracture efficacy of bisphosphonatesMichael Pazianas, Solomon Epstein, Mone Zaidi
Annals of the New York Academy of Sciences|July 13, 2006
Modeling of serum C-telopeptide levels with daily and monthly oral ibandronate in humansMone Zaidi, Solomon Epstein, Keith Friend
Acta Diabetologica|January 16, 2018
Insulin resistance and bone: a biological partnershipCaterina Conte, Solomon Epstein, Nicola Napoli
Journal of Clinical Pharmacology|August 20, 2004
Ibandronate: a clinical pharmacological and pharmacokinetic updateJoanne Barrett, Eric Worth, Frieder Bauss, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|December 16, 2003
Disorders associated with acute rapid and severe bone lossSolomon Epstein, Angela M Inzerillo, John Caminis, et al.
JAMA|December 28, 2006
Long-term proton pump inhibitor therapy and risk of hip fractureYu-Xiao Yang, James D Lewis, Solomon Epstein, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Current Osteoporosis Reports|March 11, 2006
Ibandronate treatment for osteoporosis: rationale, preclinical, and clinical development of extended dosing regimensSolomon Epstein
Clinical Therapeutics|May 9, 2006
Update of current therapeutic options for the treatment of postmenopausal osteoporosisSolomon Epstein
Mayo Clinic Proceedings|March 11, 2005
The roles of bone mineral density, bone turnover, and other properties in reducing fracture risk during antiresorptive therapySolomon Epstein
Annals of the New York Academy of Sciences|July 13, 2006
Nonsteroid immune modulators and bone diseaseRonald Tamler, Solomon Epstein
Reviews on Recent Clinical Trials|May 26, 2009
Evaluating the antifracture efficacy of bisphosphonatesMichael Pazianas, Solomon Epstein, Mone Zaidi
Annals of the New York Academy of Sciences|July 13, 2006
Modeling of serum C-telopeptide levels with daily and monthly oral ibandronate in humansMone Zaidi, Solomon Epstein, Keith Friend
Acta Diabetologica|January 16, 2018
Insulin resistance and bone: a biological partnershipCaterina Conte, Solomon Epstein, Nicola Napoli
Journal of Clinical Pharmacology|August 20, 2004
Ibandronate: a clinical pharmacological and pharmacokinetic updateJoanne Barrett, Eric Worth, Frieder Bauss, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|December 16, 2003
Disorders associated with acute rapid and severe bone lossSolomon Epstein, Angela M Inzerillo, John Caminis, et al.
JAMA|December 28, 2006
Long-term proton pump inhibitor therapy and risk of hip fractureYu-Xiao Yang, James D Lewis, Solomon Epstein, et al.
Pageof 3